HU177 collagen neo-epitope (HU177)

The HU177 collagen neo-epitope is a cryptic site within the triple-helical structure of various collagen types (I, II, III, IV, and V) that becomes exposed only upon proteolytic degradation or denaturation. This epitope is selectively generated in the tumor microenvironment and at sites of active pathological remodeling, while remaining hidden in intact, healthy tissues. It serves as a functional regulatory element that promotes the adhesion, migration, and proliferation of endothelial cells and alpha-smooth muscle actin-expressing stromal cells, often through interactions with integrins such as alpha-10-beta-1. Therapeutic targeting of the HU177 epitope with monoclonal antibodies like TRC093 (D93) has demonstrated the ability to inhibit tumor-associated angiogenesis and restrict the accumulation of pro-tumorigenic stromal cells in preclinical models and early clinical trials. Additionally, the presence of the shed HU177 epitope in patient serum has been explored as a potential biomarker for disease progression and prognosis in cancers like melanoma. By specifically targeting the denatured form of collagen, these therapies aim to disrupt the supportive tumor microenvironment with minimal impact on healthy, intact tissues.

Other names

Cryptic collagen epitope HU177Denatured collagen neo-epitopeHU177 epitopeCryptic ECM epitope HU177

Monoclonal antibodies bind to the cryptic HU177 epitope on denatured collagen, blocking the interaction between the extracellular matrix and cell surface receptors like integrin alpha-10-beta-1. This disruption inhibits the adhesion, migration, and proliferation of endothelial and stromal cells, thereby suppressing angiogenesis and tumor growth.